# A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

> **NCT07734844** · PHASE3 · RECRUITING · sponsor: **Kodiak Sciences Inc** · enrollment: 910 (estimated)

## Conditions studied

- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** Tabirafusp tedromer
- **DRUG:** Aflibercept (2.0 mg)

## Key facts

- **NCT ID:** NCT07734844
- **Lead sponsor:** Kodiak Sciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-03
- **Primary completion:** 2028-08-31
- **Final completion:** 2029-09
- **Target enrollment:** 910 (ESTIMATED)
- **Last updated:** 2026-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734844, "A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*